Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Morbus Parkinson / Parkinson's Disease (PD) & Drugs/Treatments

Navigation

Contents

Morbus Parkinson / Parkinson's Disease (PD) is treated symptomatically as no causative drug or procedure has been successfully established for clinical use.
Grotemeyer et al. 2022 Front. Immunol. 13: 878771

Levodopa is the most commonly used drug in the treatment of Morbus Parkinson / Parkinson's Disease (PD)
Perez-Pardo et al. 2017 Eur. J. Pharm. 817: 86-95

Some alternatives to standard of care (SoC) are Exercise / physical activity and acupuncture
Feng et al. 2020a Life Sci 245: 10
Wen et al. 2021 Front Aging Neurosci 13: 676827

see also:
Benserazide + Levodopa (L-DOPA) & Morbus Parkinson / Parkinson's Disease (PD)
Carbidopa + Levodopa (L-DOPA) & Morbus Parkinson / Parkinson's Disease (PD)
Fecal Microbiota Transplantation (FMT) & Morbus Parkinson / Parkinson's Disease (PD)
Levodopa (L-DOPA) + Selegiline & Morbus Parkinson / Parkinson's Disease (PD)
Probiotics (living agents) & Morbus Parkinson / Parkinson's Disease (PD)

References (Sources)

A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned.
Group 2017 Parkinsonism Relat Disord. 37: 101-5
Acupuncture-related therapies for Parkinson’s disease: a metaanalysis and qualitative review
Wen et al. 2021 Front Aging Neurosci 13: 676827
Review
Co-transplantation of autologous Treg cells in a cell therapy for Parkinson’s disease
Park et al. 2023a Nature 619: 606-615
Is a cure for Parkinson’s disease hiding inside us?
Santos et al. 2022 Trends in Biochemical Sciences 47: 641
Managing autonomic dysfunction in Parkinson’s disease: a review of emerging drugs
Kulshreshtha et al. 2020 Expert Opin. Emerging Drugs 25: 37-47
Review
Neuroinﬂammation in Parkinson’s Disease – Putative Pathomechanisms and Targets for Disease-Modiﬁcation
Grotemeyer et al. 2022 Front. Immunol. 13: 878771
Parkinson’s disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis
DeMaagd & Philip 2015 P T 40: 504-532
Phytotherapy in treatment of Parkinson’s disease: a review
Rabiei et al. 2019 Pharm Biol 57: 355-362
Review
The beneﬁts and mechanisms of exercise training for Parkinson’s disease
Feng et al. 2020a Life Sci 245: 10
Review
The gut-brain axis in Parkinson’s disease: Possibilities for food-based therapies
Perez-Pardo et al. 2017 Eur. J. Pharm. 817: 86-95

0-10 / 11

AI Chat

11/5/2026

Chat with our artificial intelligence:

Links

Antiparkinson medication - Wikipedia